Dimensional Fund Advisors’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Dimensional Fund Advisors's DNLI Position: Q3 2026 in Review
Dimensional Fund Advisors increased its Denali Therapeutics (DNLI) stake by 2% in Q3 2026, buying an estimated $1.36M and bringing the position to 2,918,830 shares worth $60.3M. The position accounts for 0.01% of the portfolio, ranked #1478.
Dimensional Fund Advisors first reported a position in DNLI in Q2 2019 and has held it in 29 quarters since. The position peaked at $73.6M in Q2 2026. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- Dimensional Fund Advisors held 2,918,830 shares of Denali Therapeutics worth $60.3M as of Q3 2026.
- Dimensional Fund Advisors bought 58,226 Denali Therapeutics shares in Q3 2026, an estimated $1.36M.
- Denali Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #1478 holding.
- Dimensional Fund Advisors first reported a position in Denali Therapeutics in Q2 2019 and has held it in 29 quarters since.
- Dimensional Fund Advisors's Denali Therapeutics position peaked at $73.6M in Q2 2026.
- 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.